Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Anne Vanlent


  • Director at Ocera Therapeutics Inc. (OCRX), 2017-12-11
  • Director at Aviragen Therapeutics Inc. (AVIR), 2017-05-22
  • Director at Applied Genetic Technologies Corp (AGTC), 2017-03-03
  • Director at Novelion Therapeutics Inc. (NVLN), 2016-12-27
  • Director at Aegerion Pharmaceuticals Inc. (AEGR), 2016-12-01
  • Director at Onconova Therapeutics Inc. (ONTX), 2015-06-17
  • Director at Integra Lifesciences Holdings Corp (IART), 2012-05-21
  • Director at Penwest Pharmaceuticals Co (PPCO), 2010-11-08
Insider Trading: Purchases See All
Company Symbol Price Amount Relationship Remaning Holdings Date Form 4
BOTA $2.20 35,000 Director 35,000 2015-06-22 Filing
AEGR $35.29 52 Director 4,000 2014-05-08 Filing
AEGR $34.33 1,948 Director 3,948 2014-05-08 Filing
AEGR $33.20 2,000 Director 2,000 2014-05-08 Filing
Insider Trading: Sales See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
IART $47.49 5,270 Director 3,478 2011-01-13 Filing